ANI Pharmaceuticals, Inc.

ANIPNASDAQHealthcare● Active

$80.96

$-0.15(-0.19%)

Market Cap$1.8B

P/E Ratio—

52W High$99.5

52W Low$59.61

Avg Volume360K

Open$81.10

Beta0.44

Overview

ANI Pharmaceuticals, Inc. (ANIP) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ANIP · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

ANI Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

ANIP insider buying and selling by quarter

ANIP insider selling · ANIP insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

468K234K0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · ANIP ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ANIP executive sell shares · ANIP board member insider trading · ANIP insider trading SEC filing

Showing 99 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 11, 2026	Walsh Patrick D Director	Sale	3,973	$80.75	$321K	48,432	Form 4
May 13, 2026	Walsh Patrick D Director	Sale	10,000	$80.63	$806K	38,432	Form 4
May 12, 2026	Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS	Sale	459	$79.21	$36K	38,271	Form 4
May 11, 2026	Lalwani Nikhil PRESIDENT & CEO · Director	Sale	55,000	$77.57	$4.27M⚡	349,889	Form 4
May 12, 2026	Gutwerg Ori SVP, GENERICS	Sale	2,772	$79.50	$220K	78,696	Form 4
May 13, 2026	Cook Meredith SR. VP, GENERAL COUNSEL & SEC.	Sale	500	$78.16	$39K	78,390	Form 4
Apr 13, 2026	Cook Meredith SR. VP, GENERAL COUNSEL & SEC.	Sale	500	$77.95	$39K	78,890	Form 4
Mar 11, 2026	Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS	Sale	4,772	$74.91	$357K	38,730	Form 4
Mar 13, 2026	Mutz Christopher HEAD OF RARE DISEASE	Sale	3,162	$71.64	$227K	91,309	Form 4
Mar 13, 2026	Cook Meredith SR. VP, GENERAL COUNSEL & SEC.	Sale	500	$72.62	$36K	79,390	Form 4
Mar 6, 2026	Mutz Christopher HEAD OF RARE DISEASE	Sale	2,121	$74.22	$157K	101,387	Form 4
Mar 7, 2026	Mutz Christopher HEAD OF RARE DISEASE	Other	3,314	$74.04	$245K	98,073	Form 4
Mar 9, 2026	Mutz Christopher HEAD OF RARE DISEASE	Sale	3,602	$74.18	$267K	94,471	Form 4
Mar 7, 2026	Lalwani Nikhil PRESIDENT & CEO · Director	Other	17,060	$74.04	$1.26M⚡	404,889	Form 4
Mar 7, 2026	Gutwerg Ori SVP, GENERICS	Other	3,314	$74.04	$245K	81,468	Form 4
Mar 6, 2026	Davis Krista SVP, CHIEF HR OFFICER	Sale	1,485	$75.00	$111K	57,033	Form 4
Mar 9, 2026	Davis Krista SVP, CHIEF HR OFFICER	Sale	5,087	$74.13	$377K	51,946	Form 4
Mar 7, 2026	CAREY STEPHEN P. SVP & CFO	Other	5,150	$74.04	$381K	180,393	Form 4
Mar 5, 2026	CAREY STEPHEN P. SVP & CFO	Option	3,312	$49.51	$164K	192,855	Form 4
Mar 5, 2026	CAREY STEPHEN P. SVP & CFO	Sale	3,312	$75.42	$250K	189,543	Form 4
Mar 5, 2026	CAREY STEPHEN P. SVP & CFO	Sale	4,000	$75.56	$302K	185,543	Form 4
Mar 2, 2026	Mutz Christopher HEAD OF RARE DISEASE	Sale	417	$74.00	$31K	103,508	Form 4
Mar 3, 2026	Gutwerg Ori SVP, GENERICS	Sale	2,060	$76.50	$158K	84,782	Form 4
Mar 3, 2026	Walsh Patrick D Director	Sale	6,000	$74.23	$445K	52,405	Form 4
Feb 26, 2026	Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS · Director	Award	11,116	$77.15	$858K	101,056	Form 4

Walsh Patrick D

Director

Sale

Date

May 11

3,973

Price

$80.75

Value

$321K

View Form 4 on SEC.gov

Walsh Patrick D

Director

Sale

Date

May 13

10,000

Price

$80.63

Value

$806K

View Form 4 on SEC.gov

Rowland Thomas Andrew

SVP, HEAD - ESTABLISHED BRANDS

Sale

Date

May 12

459

Price

$79.21

Value

$36K

View Form 4 on SEC.gov

Lalwani Nikhil

PRESIDENT & CEO · Director

Sale

Date

May 11

55,000

Price

$77.57

Value

$4.27M ⚡

View Form 4 on SEC.gov

Gutwerg Ori

SVP, GENERICS

Sale

Date

May 12

2,772

Price

$79.50

Value

$220K

View Form 4 on SEC.gov

Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Sale

Date

May 13

500

Price

$78.16

Value

$39K

View Form 4 on SEC.gov

Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Sale

Date

Apr 13

500

Price

$77.95

Value

$39K

View Form 4 on SEC.gov

Rowland Thomas Andrew

SVP, HEAD - ESTABLISHED BRANDS

Sale

Date

Mar 11

4,772

Price

$74.91

Value

$357K

View Form 4 on SEC.gov

Mutz Christopher

HEAD OF RARE DISEASE

Sale

Date

Mar 13

3,162

Price

$71.64

Value

$227K

View Form 4 on SEC.gov

Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Sale

Date

Mar 13

500

Price

$72.62

Value

$36K

View Form 4 on SEC.gov

Mutz Christopher

HEAD OF RARE DISEASE

Sale

Date

Mar 6

2,121

Price

$74.22

Value

$157K

View Form 4 on SEC.gov

Mutz Christopher

HEAD OF RARE DISEASE

Other

Date

Mar 7

3,314

Price

$74.04

Value

$245K

View Form 4 on SEC.gov

Mutz Christopher

HEAD OF RARE DISEASE

Sale

Date

Mar 9

3,602

Price

$74.18

Value

$267K

View Form 4 on SEC.gov

Lalwani Nikhil

PRESIDENT & CEO · Director

Other

Date

Mar 7

17,060

Price

$74.04

Value

$1.26M ⚡

View Form 4 on SEC.gov

Gutwerg Ori

SVP, GENERICS

Other

Date

Mar 7

3,314

Price

$74.04

Value

$245K

View Form 4 on SEC.gov

Davis Krista

SVP, CHIEF HR OFFICER

Sale

Date

Mar 6

1,485

Price

$75.00

Value

$111K

View Form 4 on SEC.gov

Davis Krista

SVP, CHIEF HR OFFICER

Sale

Date

Mar 9

5,087

Price

$74.13

Value

$377K

View Form 4 on SEC.gov

CAREY STEPHEN P.

SVP & CFO

Other

Date

Mar 7

5,150

Price

$74.04

Value

$381K

View Form 4 on SEC.gov

CAREY STEPHEN P.

SVP & CFO

Option

Date

Mar 5

3,312

Price

$49.51

Value

$164K

View Form 4 on SEC.gov

CAREY STEPHEN P.

SVP & CFO

Sale

Date

Mar 5

3,312

Price

$75.42

Value

$250K

View Form 4 on SEC.gov

CAREY STEPHEN P.

SVP & CFO

Sale

Date

Mar 5

4,000

Price

$75.56

Value

$302K

View Form 4 on SEC.gov

Mutz Christopher

HEAD OF RARE DISEASE

Sale

Date

Mar 2

417

Price

$74.00

Value

$31K

View Form 4 on SEC.gov

Gutwerg Ori

SVP, GENERICS

Sale

Date

Mar 3

2,060

Price

$76.50

Value

$158K

View Form 4 on SEC.gov

Walsh Patrick D

Director

Sale

Date

Mar 3

6,000

Price

$74.23

Value

$445K

View Form 4 on SEC.gov

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS · Director

Award

Date

Feb 26

11,116

Price

$77.15

Value

$858K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 4

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ANIP insider trading

ANIP insider trades

ANI Pharmaceuticals, Inc. (ANIP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.), Davis Krista (SVP, CHIEF HR OFFICER), Mutz Christopher (HEAD OF RARE DISEASE). Over the past 12 months, 5 insiders have filed transactions with the SEC. ANIP insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For ANI Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

ANIP insider trading · 5 questions

The insiders of ANI Pharmaceuticals, Inc. (ANIP) include executives and directors such as Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.), Davis Krista (SVP, CHIEF HR OFFICER), Mutz Christopher (HEAD OF RARE DISEASE), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ANIP board member insider tradingwho are ANIP insidersANIP insider rosterANI Pharmaceuticals, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026